FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1892568960> ?p ?o ?g. }

• W1892568960 endingPage "305" @default.
• W1892568960 startingPage "301" @default.
• W1892568960 abstract "Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC.We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. Variability among patient backgrounds was evaluated using propensity scores to assess comparability. The efficacy of these agents was evaluated in patient subgroups with low variability.The propensity scores showed that the backgrounds of the groups that received second-line therapy with each agent had low variability and were adequate for comparison. Patients were divided into the PS0/1 and PS2 groups for analysis. The median progression-free survival (PFS) in patients treated with erlotinib was 2.8 months in the PS0/1 group, as compared with 1.0 month in the PS0/1/2 group and 0.90 months in the PS2 group. PFS in PS0/1 patients who received erlotinib was comparable to that in PS0/1 patients who received pemetrexed (2.5 months) or docetaxel (1.9 months). Overall survival (OS) in erlotinib-, pemetrexed-, and docetaxel-treated PS0/1 patients was 16.1, 7.4 and 10.0 months, respectively. The study had limited power to detect differences in PFS and OS because of the small sample size.Erlotinib appears to be a useful second-line option in PS0/1 patients with EGFR mutation-negative advanced non-squamous NSCLC given its mild adverse effects. The results should be carefully interpreted because of the small sample size, limited power, and retrospective nature of the study." @default.
• W1892568960 created "2016-06-24" @default.
• W1892568960 creator A5000653374 @default.
• W1892568960 creator A5001730366 @default.
• W1892568960 creator A5011349417 @default.
• W1892568960 creator A5022022857 @default.
• W1892568960 creator A5024943202 @default.
• W1892568960 creator A5032960175 @default.
• W1892568960 creator A5034733511 @default.
• W1892568960 creator A5039573714 @default.
• W1892568960 creator A5041720877 @default.
• W1892568960 creator A5053572336 @default.
• W1892568960 creator A5060874420 @default.
• W1892568960 creator A5071117344 @default.
• W1892568960 creator A5080717730 @default.
• W1892568960 creator A5080938148 @default.
• W1892568960 creator A5090494204 @default.
• W1892568960 date "2015-09-01" @default.
• W1892568960 modified "2023-09-25" @default.
• W1892568960 title "Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR -mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer" @default.
• W1892568960 cites W2005244154 @default.
• W1892568960 cites W2037791152 @default.
• W1892568960 cites W2095496928 @default.
• W1892568960 cites W2099725888 @default.
• W1892568960 cites W2100912832 @default.
• W1892568960 cites W2105026490 @default.
• W1892568960 cites W2111662961 @default.
• W1892568960 cites W2144180913 @default.
• W1892568960 cites W2144330816 @default.
• W1892568960 cites W2150291618 @default.
• W1892568960 cites W2160040938 @default.
• W1892568960 cites W2160982674 @default.
• W1892568960 cites W2165771694 @default.
• W1892568960 doi "https://doi.org/10.1016/j.lungcan.2015.06.017" @default.
• W1892568960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26141215" @default.
• W1892568960 hasPublicationYear "2015" @default.
• W1892568960 type Work @default.
• W1892568960 sameAs 1892568960 @default.
• W1892568960 citedByCount "10" @default.
• W1892568960 countsByYear W18925689602016 @default.
• W1892568960 countsByYear W18925689602017 @default.
• W1892568960 countsByYear W18925689602018 @default.
• W1892568960 countsByYear W18925689602019 @default.
• W1892568960 countsByYear W18925689602020 @default.
• W1892568960 countsByYear W18925689602021 @default.
• W1892568960 countsByYear W18925689602023 @default.
• W1892568960 crossrefType "journal-article" @default.
• W1892568960 hasAuthorship W1892568960A5000653374 @default.
• W1892568960 hasAuthorship W1892568960A5001730366 @default.
• W1892568960 hasAuthorship W1892568960A5011349417 @default.
• W1892568960 hasAuthorship W1892568960A5022022857 @default.
• W1892568960 hasAuthorship W1892568960A5024943202 @default.
• W1892568960 hasAuthorship W1892568960A5032960175 @default.
• W1892568960 hasAuthorship W1892568960A5034733511 @default.
• W1892568960 hasAuthorship W1892568960A5039573714 @default.
• W1892568960 hasAuthorship W1892568960A5041720877 @default.
• W1892568960 hasAuthorship W1892568960A5053572336 @default.
• W1892568960 hasAuthorship W1892568960A5060874420 @default.
• W1892568960 hasAuthorship W1892568960A5071117344 @default.
• W1892568960 hasAuthorship W1892568960A5080717730 @default.
• W1892568960 hasAuthorship W1892568960A5080938148 @default.
• W1892568960 hasAuthorship W1892568960A5090494204 @default.
• W1892568960 hasConcept C121608353 @default.
• W1892568960 hasConcept C126322002 @default.
• W1892568960 hasConcept C143998085 @default.
• W1892568960 hasConcept C2776256026 @default.
• W1892568960 hasConcept C2776694085 @default.
• W1892568960 hasConcept C2777240266 @default.
• W1892568960 hasConcept C2778087573 @default.
• W1892568960 hasConcept C2778239845 @default.
• W1892568960 hasConcept C2779438470 @default.
• W1892568960 hasConcept C2781190966 @default.
• W1892568960 hasConcept C71924100 @default.
• W1892568960 hasConceptScore W1892568960C121608353 @default.
• W1892568960 hasConceptScore W1892568960C126322002 @default.
• W1892568960 hasConceptScore W1892568960C143998085 @default.
• W1892568960 hasConceptScore W1892568960C2776256026 @default.
• W1892568960 hasConceptScore W1892568960C2776694085 @default.
• W1892568960 hasConceptScore W1892568960C2777240266 @default.
• W1892568960 hasConceptScore W1892568960C2778087573 @default.
• W1892568960 hasConceptScore W1892568960C2778239845 @default.
• W1892568960 hasConceptScore W1892568960C2779438470 @default.
• W1892568960 hasConceptScore W1892568960C2781190966 @default.
• W1892568960 hasConceptScore W1892568960C71924100 @default.
• W1892568960 hasIssue "3" @default.
• W1892568960 hasLocation W18925689601 @default.
• W1892568960 hasLocation W18925689602 @default.
• W1892568960 hasOpenAccess W1892568960 @default.
• W1892568960 hasPrimaryLocation W18925689601 @default.
• W1892568960 hasRelatedWork W1892568960 @default.
• W1892568960 hasRelatedWork W1964921655 @default.
• W1892568960 hasRelatedWork W1966598656 @default.
• W1892568960 hasRelatedWork W1974243887 @default.
• W1892568960 hasRelatedWork W1998118269 @default.
• W1892568960 hasRelatedWork W2045163220 @default.
• W1892568960 hasRelatedWork W2125324728 @default.
• W1892568960 hasRelatedWork W2272416128 @default.
• W1892568960 hasRelatedWork W2588941777 @default.

• next